[Form 4] CYTOKINETICS INC Insider Trading Activity

Rhea-AI Filing Summary

Cytokinetics EVP Research & Development Fady Ibraham Malik reported a small tax-related share sale. He sold 2,907 shares of Common Stock on March 9, 2026 in an open-market transaction at $60.72 per share.

According to the footnote, this was a sell-to-cover transaction to satisfy company tax withholding obligations upon the vesting of restricted stock units, rather than a discretionary sale. After the transaction, he directly holds 138,629 shares of Cytokinetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		S(1)		2,907	D	$60.72	138,629	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cytokinetics (CYTK) report for EVP Fady Malik?

Cytokinetics EVP Fady Ibraham Malik sold 2,907 shares of common stock. The sale occurred on March 9, 2026, and was executed at $60.72 per share in an open-market transaction reported on Form 4.

Why did Cytokinetics EVP Fady Malik sell 2,907 CYTK shares?

The 2,907-share sale by EVP Fady Ibraham Malik was a sell-to-cover transaction. It was made specifically to satisfy company tax withholding obligations triggered by the vesting of restricted stock units (RSUs).

What price did Fady Malik receive for the Cytokinetics (CYTK) shares sold?

Fady Ibraham Malik sold 2,907 Cytokinetics common shares at an average price of $60.72 per share. This open-market transaction was disclosed as part of a tax-related sell-to-cover event tied to RSU vesting.

How many Cytokinetics (CYTK) shares does Fady Malik hold after this Form 4 transaction?

Following the reported sale, EVP Fady Ibraham Malik directly holds 138,629 shares of Cytokinetics common stock. This figure reflects his remaining ownership after selling 2,907 shares to cover tax withholding obligations from RSU vesting.

Was the Fady Malik CYTK share sale a discretionary sale or tax-related?

The sale was tax-related rather than purely discretionary. A footnote explains it was a sell-to-cover transaction, executed to satisfy company tax withholding obligations arising when Malik’s restricted stock units vested.